{"transactions":[{"id":1810990,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":4,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-10T13:03:21.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":3157894,"price":0.125,"value":394736.75,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Purchase was made pursuant to that certain Securities Purchase Agreement dated as of August 7, 2023, by and among the Issuer and the purchasers named therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These warrants expire at 5:00 p.m. on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023, provided that the holder will be prohibited from exercising these warrants if, after giving effect to such exercise, the holder (together with such holder's affiliates and any other persons acting as a group together) would beneficially own in excess of 9.99% of the shares of common stock of the Issuer outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These warrants expire at 5:00 p.m. on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023, provided that the holder will be prohibited from exercising these warrants if, after giving effect to such exercise, the holder (together with such holder's affiliates and any other persons acting as a group together) would beneficially own in excess of 9.99% of the shares of common stock of the Issuer outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As the managing members of Vivo Opportunity, LLC, Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P., but each disclaims beneficial ownership of such securities except to the extent of their individual pecuniary interest therein."}],"balance_after":3157894,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":3157894},"source":{"system":"sec-edgar","filing":"0001213900-23-065297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000121390023065297/ownership.xml","form_type":"4"}},{"id":1810989,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":4,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T13:03:21.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":3157894,"price":1.9,"value":5999998.6,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Purchase was made pursuant to that certain Securities Purchase Agreement dated as of August 7, 2023, by and among the Issuer and the purchasers named therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As the managing members of Vivo Opportunity, LLC, Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P., but each disclaims beneficial ownership of such securities except to the extent of their individual pecuniary interest therein."}],"balance_after":3157894,"source":{"system":"sec-edgar","filing":"0001213900-23-065297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000121390023065297/ownership.xml","form_type":"4"}},{"id":2217391,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":75749,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC (\"Vivo Ventures LLC\") is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Vivo Ventures LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":75749},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217390,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1455384,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Opportunity, LLC (\"Vivo Opportunity LLC\") is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":1455384},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217389,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":324740,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":324740},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217388,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":431947,"price":55,"value":23757085.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217387,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":2735853,"price":55,"value":150471915.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Opportunity, LLC (\"Vivo Opportunity LLC\") is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217386,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":161712,"price":55,"value":8894160.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC (\"Vivo Ventures LLC\") is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Vivo Ventures LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2280951,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T22:55:08.000Z","date":"2022-05-05","kind":"sale","acquired":false,"shares":5374,"price":12.25,"value":65831.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.33, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2469001,"source":{"system":"sec-edgar","filing":"0001213900-22-024317","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390022024317/ownership.xml","form_type":"4"}},{"id":2282462,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T00:01:39.000Z","date":"2022-05-04","kind":"sale","acquired":false,"shares":19738,"price":12.67,"value":250080.46,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 12.25 to $13.00 inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2474375,"source":{"system":"sec-edgar","filing":"0001213900-22-024052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390022024052/ownership.xml","form_type":"4"}},{"id":2282461,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T00:01:39.000Z","date":"2022-05-03","kind":"sale","acquired":false,"shares":451418,"price":13.25,"value":5981288.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.05 to $13.89, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2494113,"source":{"system":"sec-edgar","filing":"0001213900-22-024052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390022024052/ownership.xml","form_type":"4"}},{"id":2282460,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T00:01:39.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":41800,"price":15.19,"value":634942.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $15.92, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2945531,"source":{"system":"sec-edgar","filing":"0001213900-22-024052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390022024052/ownership.xml","form_type":"4"}},{"id":2421164,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-31T21:30:36.000Z","date":"2022-01-31","kind":"purchase","acquired":true,"shares":800000,"price":27,"value":21600000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2735853,"source":{"system":"sec-edgar","filing":"0001213900-22-004647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004647/ownership.xml","form_type":"4"}},{"id":2422603,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":324740,"price":13.2,"value":4286568.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":107164},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422602,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":1455384,"price":13.2,"value":19211068.8,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":480277},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422601,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":75749,"price":13.2,"value":999886.8,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":24996},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422600,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":107164,"price":13.2,"value":1414564.8,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":431947,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422599,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":480277,"price":13.2,"value":6339656.4,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1935853,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422598,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":24996,"price":13.2,"value":329947.2,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":161712,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2515550,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"ten_percent_owner":true}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:16:14.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":188168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2365545},"source":{"system":"sec-edgar","filing":"0001140361-21-037658","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037658/form4.xml","form_type":"4"}},{"id":2515549,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"ten_percent_owner":true}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:14.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":650000,"price":14,"value":9100000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein"}],"balance_after":3015545,"source":{"system":"sec-edgar","filing":"0001140361-21-037658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037658/form4.xml","form_type":"4"}},{"id":2515548,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"ten_percent_owner":true}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:16:14.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":2365545,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein"}],"balance_after":2365545,"source":{"system":"sec-edgar","filing":"0001140361-21-037658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037658/form4.xml","form_type":"4"}},{"id":2655008,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-26T01:30:34.000Z","date":"2021-06-25","kind":"sale","acquired":false,"shares":7704,"price":29.6,"value":228038.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.0 to $29.5, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2987331,"source":{"system":"sec-edgar","filing":"0001213900-21-034310","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390021034310/ownership.xml","form_type":"4"}},{"id":2655007,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-26T01:30:34.000Z","date":"2021-06-24","kind":"sale","acquired":false,"shares":10000,"price":29.9,"value":299000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2 to $29.7, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2995035,"source":{"system":"sec-edgar","filing":"0001213900-21-034310","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390021034310/ownership.xml","form_type":"4"}},{"id":2655006,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-26T01:30:34.000Z","date":"2021-06-23","kind":"sale","acquired":false,"shares":37980,"price":29.8,"value":1131804.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.6 to $28.3, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":3005035,"source":{"system":"sec-edgar","filing":"0001213900-21-034310","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390021034310/ownership.xml","form_type":"4"}},{"id":2655004,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-26T00:51:40.000Z","date":"2021-06-22","kind":"sale","acquired":false,"shares":110000,"price":28.5,"value":3135000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.0 to $28.1, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":3043015,"source":{"system":"sec-edgar","filing":"0001213900-21-034298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390021034298/ownership.xml","form_type":"4"}},{"id":2655003,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-26T00:51:40.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":91620,"price":29.7,"value":2721114.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.1 to $29.0, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":3153015,"source":{"system":"sec-edgar","filing":"0001213900-21-034298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390021034298/ownership.xml","form_type":"4"}},{"id":2747207,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-17T01:07:43.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":400,"price":30.37,"value":12148.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person inadvertently sold 400 shares of Tarsus Pharmaceuticals, Inc.'s common stock reported herein, which was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's purchase of 400 shares of Tarsus Pharmaceuticals, Inc.'s common stock at a price of $16 per share in connection with the initial public offering on October 20, 2020. The reporting person has agreed to pay to Tarsus Pharmaceuticals, Inc., upon settlement of the sale, $5,735.93, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.25 to $30.50, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":3244635,"source":{"system":"sec-edgar","filing":"0001213900-21-021965","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000121390021021965/ownership.xml","form_type":"4"}},{"id":2772035,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-03-25T17:32:43.000Z","date":"2021-03-23","kind":"exercise","acquired":false,"shares":397576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Vivo Capital Fund IX, L.P. (\"Fund IX\"). Vivo Capital IX, LLC (\"Capital IX\") is the general partner of Fund IX. As the\nmanaging members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share\nvoting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of\ntheir individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":477091},"source":{"system":"sec-edgar","filing":"0001209191-21-023066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000120919121023066/doc4.xml","form_type":"4"}},{"id":2772034,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-03-25T17:32:43.000Z","date":"2021-03-23","kind":"exercise","acquired":false,"shares":9758080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Vivo Capital Fund IX, L.P. (\"Fund IX\"). Vivo Capital IX, LLC (\"Capital IX\") is the general partner of Fund IX. As the\nmanaging members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share\nvoting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of\ntheir individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11709696},"source":{"system":"sec-edgar","filing":"0001209191-21-023066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000120919121023066/doc4.xml","form_type":"4"}},{"id":2772033,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T17:32:43.000Z","date":"2021-03-23","kind":"purchase","acquired":true,"shares":300000,"price":20,"value":6000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Vivo Capital Fund IX, L.P. (\"Fund IX\"). Vivo Capital IX, LLC (\"Capital IX\") is the general partner of Fund IX. As the\nmanaging members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share\nvoting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of\ntheir individual pecuniary interest therein."}],"balance_after":12486787,"source":{"system":"sec-edgar","filing":"0001209191-21-023066","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000120919121023066/doc4.xml","form_type":"4"}},{"id":2772032,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T17:32:43.000Z","date":"2021-03-23","kind":"exercise","acquired":true,"shares":477091,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Vivo Capital Fund IX, L.P. (\"Fund IX\"). Vivo Capital IX, LLC (\"Capital IX\") is the general partner of Fund IX. As the\nmanaging members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share\nvoting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of\ntheir individual pecuniary interest therein."}],"balance_after":12186787,"source":{"system":"sec-edgar","filing":"0001209191-21-023066","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000120919121023066/doc4.xml","form_type":"4"}},{"id":2772031,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T17:32:43.000Z","date":"2021-03-23","kind":"exercise","acquired":true,"shares":11709696,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Vivo Capital Fund IX, L.P. (\"Fund IX\"). Vivo Capital IX, LLC (\"Capital IX\") is the general partner of Fund IX. As the\nmanaging members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share\nvoting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of\ntheir individual pecuniary interest therein."}],"balance_after":11709696,"source":{"system":"sec-edgar","filing":"0001209191-21-023066","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000120919121023066/doc4.xml","form_type":"4"}},{"id":3003140,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-10-20T23:58:22.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":214281,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P.  Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.  As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214281},"source":{"system":"sec-edgar","filing":"0001209191-20-055423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055423/doc4.xml","form_type":"4"}},{"id":3003139,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-20T23:58:22.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":2780754,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P.  Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.  As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2780754},"source":{"system":"sec-edgar","filing":"0001209191-20-055423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055423/doc4.xml","form_type":"4"}},{"id":3003138,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T23:58:22.000Z","date":"2020-10-20","kind":"purchase","acquired":true,"shares":250000,"price":16,"value":4000000.0,"ownership":{"direct":true},"balance_after":3245035,"source":{"system":"sec-edgar","filing":"0001209191-20-055423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055423/doc4.xml","form_type":"4"}},{"id":3003137,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T23:58:22.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":214281,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P.  Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.  As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2995035,"source":{"system":"sec-edgar","filing":"0001209191-20-055423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055423/doc4.xml","form_type":"4"}},{"id":3003136,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T23:58:22.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":2780754,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Vivo Capital Fund IX, L.P.  Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.  As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2780754,"source":{"system":"sec-edgar","filing":"0001209191-20-055423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055423/doc4.xml","form_type":"4"}},{"id":3078896,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":4,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T00:25:08.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":3158851,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund IX, L.P. (VIVO IX LP). Vivo Capital IX, LLC (VIVO IX LLC) is the General Partner of VIVO IX LP. As the managing members of Vivo Capital IX, LLC, Frank Kung, Albert Cha, Edgar Engleman, Shan Fu and Chen Yu share voting and dispositive power with respect to the shares held of record by VIVO IX LP but each disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3158851},"source":{"system":"sec-edgar","filing":"0000899243-20-019915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019915/doc4.xml","form_type":"4"}},{"id":3078895,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":4,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T00:25:08.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":185526,"price":19,"value":3524994.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by Vivo Opportunity Fund, L.P. (VOF). Vivo Opportunity, LLC is the general partner of VOF. As the managing members of Vivo Opportunity, LLC, Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang share voting and dispositive power with respect to the shares held of record by VIVO IX LP but each disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":185526,"source":{"system":"sec-edgar","filing":"0000899243-20-019915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019915/doc4.xml","form_type":"4"}},{"id":3078894,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":4,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T00:25:08.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3245048,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 86,197 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund IX, L.P. (VIVO IX LP). Vivo Capital IX, LLC (VIVO IX LLC) is the General Partner of VIVO IX LP. As the managing members of Vivo Capital IX, LLC, Frank Kung, Albert Cha, Edgar Engleman, Shan Fu and Chen Yu share voting and dispositive power with respect to the shares held of record by VIVO IX LP but each disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":4034522,"source":{"system":"sec-edgar","filing":"0000899243-20-019915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019915/doc4.xml","form_type":"4"}},{"id":3078893,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":4,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T00:25:08.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":789474,"price":19,"value":15000006.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund IX, L.P. (VIVO IX LP). Vivo Capital IX, LLC (VIVO IX LLC) is the General Partner of VIVO IX LP. As the managing members of Vivo Capital IX, LLC, Frank Kung, Albert Cha, Edgar Engleman, Shan Fu and Chen Yu share voting and dispositive power with respect to the shares held of record by VIVO IX LP but each disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":789474,"source":{"system":"sec-edgar","filing":"0000899243-20-019915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019915/doc4.xml","form_type":"4"}},{"id":3296793,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":4287,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F8","text":"Consists of 4,287 shares of Series A Preferred Stock held by Vivo Capital Fund IX, L.P., which are convertible into an aggregate of 324,783 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":324783},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296792,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":19213,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F7","text":"Consists of 19,213 shares of Series A Preferred Stock held by Vivo Opportunity Fund, L.P., which are convertible into an aggregate of 1,455,576 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1455576},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296791,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":1000,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F6","text":"Consists of 1,000 shares of Series A Preferred Stock held by Vivo Fund VII, which are convertible into an aggregate of 75,759 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":75759},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296790,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":324783,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":324783,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296789,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":1455576,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1455576,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296788,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":75759,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":136715,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}}]}